The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mr. Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, has disclosed the purchase of 8,400 equity shares of the company on March 11, 2026, through the open market. His holding in the company increased from 6,97,300 shares (30.55%) to 7,05,700 shares (30.92%) post-acquisition. The increase in stake is marginal at 0.37 percentage points. The total equity share capital of the company remains at 22,82,400 shares. The disclosure has been filed with both the company and BSE as required under SEBI Takeover Regulations.
This is a small incremental purchase by the promoter, indicating confidence in the company, but the 0.37% increase is not material enough to significantly impact shareholding pattern or stock price. It is a mildly positive signal of promoter faith.